NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

NDA.FI

15.87

+0.13%↑

DIM

162.25

+4.14%↑

BKT

13.852

+0.22%↑

FCFS

225.07

+1.44%↑

RAND

25.255

+0.28%↑

Inicio・Lista de Acciones・DBV Technologies SA

Search

D
DBV Technologies SA

Cerrado

3.608 1.58

Resumen

Variación precio

24h

Actual

Mínimo

3.602

Máximo

3.642

Métricas clave
By Trading Economics
Ingresos	-12M -45M
Ventas	3.4M 3.4M
Margen de beneficios	-1,323.179
Empleados	117
EBITDA	-10M -42M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-10.19% downside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	619M 1B
Apertura anterior	2.03
Cierre anterior	3.608

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

1.61 / 1.72 Soporte y Resistencia

DBV Technologies SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 may 2026, 22:17 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 may 2026, 23:47 UTC

Ganancias

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 may 2026, 23:45 UTC

Ganancias

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 may 2026, 23:40 UTC

Charlas de Mercado

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 may 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 may 2026, 22:42 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 may 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Shareholders to Own About 51% of Combined Company

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Board Unanimously Endorsed, Supported Deal

4 may 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Regis: Deal Unanimously Recommended by Vault Board

4 may 2026, 22:39 UTC

Adquisiciones, fusiones, absorciones

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources to Acquire All Ordinary Shares in Vault

4 may 2026, 22:38 UTC

Adquisiciones, fusiones, absorciones

Regis Resources, Vault Minerals Agree to Merger of Equals

4 may 2026, 22:37 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 may 2026, 22:26 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 may 2026, 22:02 UTC

Ganancias

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 may 2026, 22:00 UTC

Charlas de Mercado

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 may 2026, 21:52 UTC

Ganancias

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 may 2026, 21:50 UTC

Ganancias

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 may 2026, 21:49 UTC

Ganancias

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 may 2026, 21:44 UTC

Ganancias

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 may 2026, 21:43 UTC

Ganancias

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 may 2026, 21:41 UTC

Ganancias

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 may 2026, 21:40 UTC

Ganancias

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparación entre iguales

Cambio de precio

DBV Technologies SA previsión

Precio Objetivo

By TipRanks

-10.19% descenso

Estimación a 12 Meses

Media 3.26 EUR -10.19%

Máximo 5.5 EUR

Mínimo 1.01 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para DBV Technologies SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

2 ratings

1

Comprar

0

Mantener

1

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para DBV Technologies SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.61 / 1.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Otras acciones del sector

NDA.FI

Nordea Bank Abp

15.87

DIM

Sartorius Stedim Biotech.

162.25

BKT

Bankinter SA

13.852

FCFS

FirstCash Inc

225.07

RAND

Randstad Holding NV

25.255

Live chat